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LETTERS
Extensively 
Drug-Resistant 
Tuberculosis,
Taiwan
To the Editor: In Taiwan, the 
incidence of tuberculosis (TB) was 
74.1/100,000 population in 2004 and 
72.7/100,000 in 2005; the mortal-
ity rate was 4.2/100,000 in 2004 and 
4.3/100,000 in 2005 (1). Because of 
these high incidences and the increas-
ing effects of multidrug-resistant TB 
(MDR TB), i.e., resistant to at least both 
isoniazid (INH) and rifampin (RIF), the 
laboratory-based Taiwan Surveillance 
of Drug Resistance in TB (TSDRTB) 
program was established in 2003 (2). 
Surveillance demonstrated that com-
bined drug resistance rates were 11.3% 
(2004) and 10.1% (2005) for INH; 7.5% 
(2004) and 6.2% (2005) for RIF; 4.3% 
(2004) and 2.1% (2005) for etham-
butol (EMB); 10.6% (2004) and 9.8% 
(2005) for streptomycin (SM); 20.4% 
(2004) and 18.1% (2005) for any ﬁ  rst-
line drug; and 5.3% (2004) and 4.0% 
(2005) for multidrug resistance. These 
resistance rates are higher than those 
reported by the third TB global drug 
resistance surveillance. Global surveil-
lance reported median prevalence of 
combined drug resistance was 6.6% 
for INH, 2.2% for RIF, 1.3% for EMB, 
6.1% for SM, 10.4% for any drug, and 
1.7% for multidrug resistance. TB (3).
Extensively drug-resistant TB 
(XDR TB) was initially deﬁ  ned as an 
MDR isolate that was resistant to at 
least 3 of the 6 main classes of second-
line drugs:  aminoglycosides, polypep-
tides,  ﬂ  uoroquinolones,  thioamides, 
cycloserine, and para-aminosalicylic 
acid (4). In October 2006, the World 
Health Organization (WHO) redeﬁ  ned 
XDR TB as an isolate “resistant to at 
least INH and RIF (i.e., MDR TB) plus 
resistant to at least 1 of the ﬂ  uoroqui-
nolones and 1 of the following 3 in-
jectable drugs: capreomycin, kanamy-
cin, and amikacin” (5). Clearly, XDR 
TB is a global threat and the demands 
on XDR TB surveillance systems are 
urgent.
Because no guidelines for drug 
susceptibility testing of second-line 
drugs existed in Taiwan before 2007, 
clinical mycobacteriology laborato-
ries performed drug susceptibility 
testing of second-line drugs using the 
agar proportion method by clinicians’ 
request only. Critical concentrations 
of second-line drugs for drug sus-
ceptibility testing were 2 μg/mL for 
oﬂ  oxacin,  6  μg/mL for kanamycin, 
10 μg/mL for ethionamide, and 8 μg/
mL for para-aminosalicylate. Of the 
215 MDR isolates, 92 (42.8%), 35 
(16.3%), 34 (15.8%), and 56 (26.0%) 
were resistant to ﬂ  uoroquinolone, 
kanamycin, ethionamide, and para-
aminosalicylate, respectively. Of the 
116 MDR isolates tested for suscep-
tibility to second-line drugs in 2004, 
10.3% (12/116) were XDR TB; of 
the 99 MDR isolates tested in 2005, 
10.1% (10/99) were XDR TB.
With their broad spectrum anti-
microbial activity, ﬂ  uoroquinolones 
are widely used for the treatment of 
bacterial respiratory infections in Tai-
wan. In addition, ﬂ  uoroquinolones are 
the preferred oral agents for treating 
drug-resistant TB that is known or 
presumed to be sensitive to this class 
of drugs, or when ﬁ  rst-line agents can-
not be used because of intolerance 
(6). In contrast to injectable agents 
that have a higher incidence of renal 
and hearing impairment after long-
term use, ﬂ  uoroquinolones have high 
oral bioavailability, convenient dos-
ing intervals, and a lower incidence 
of side effects (7). Therefore, despite 
TB treatment recommendations, some 
clinicians prescribe ﬂ  uoroquinolones 
instead of injectable agents. A pre-
vious study by Yu et al. (8) showed 
that  ﬂ  uoroquinolone-resistant  Myco-
bacterium tuberculosis isolates were 
rare among patients not previously 
exposed to ﬂ  uoroquinolones; howev-
er, the increased rate of resistance to 
ﬂ  uoroquinolones was observed among 
patients with MDR TB because of in-
adequate treatment regimens or poor 
compliance (8,9).
In this study, 215 MDR isolates 
were tested; among these, 42.8% 
(92/215) were ﬂ  uoroquinolone-resis-
tant, a much higher percentage than 
the 10.2% (22/215) that fulﬁ  lled the 
deﬁ  nition of XDR TB. Because the ad-
equate use of ﬂ  uoroquinolones for TB 
per WHO and national guidelines (ei-
ther for intolerance or drug resistance) 
is important, the use of ﬂ  uoroquinolo-
nes is strictly regulated by the National 
Health Insurance program. Since 2007, 
clinicians in Taiwan have been required 
to apply for these and second-line 
drugs through the Taiwan Centers for 
Disease Control (CDC) and to accept 
professional supervision in their ad-
ministration. Furthermore, these drugs 
can only be given under the direct 
observed treatment program. 
An outbreak in rural South Af-
rica highlighted the risk of XDR TB 
for persons co-infected with HIV (10). 
The current Taiwan TB and HIV Reg-
ister shows that <1% of TB patients 
are co-infected with HIV and docu-
ments no XDR TB patients who are 
co-infected with HIV. However, be-
cause persons co-infected with HIV 
and M. tuberculosis have the highest 
rates of progression to active disease, 
continued monitoring of co-infected 
patients is essential for control of TB.
The initial purpose of the TS-
DRTB program was to survey drug re-
sistance of ﬁ  rst-line anti-TB drugs in 
Taiwan. Therefore, our study data are 
limited; the rate of XDR TB among 
MDR TB may be an underestimate 
because we did not have adequate 
representative cases and methods. 
The present surveillance system does 
clearly show the emergence of XDR 
TB cases in Taiwan, which highlights 
the need to reinforce diagnosis and 
treatment strategies recommended by 
the National TB Control Program.  In 
addition to the established TSDRTB 
program, Taiwan CDC started an en-
hanced population-based surveillance 
of MDR TB/XDR TB in 2007. 
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Hantavirus 
Outbreak, 
Germany, 2007
To the Editor: Hantavirus disease 
(for review see [1]) has been report-
able in Germany since 2001, accord-
ing to the Federal Infection Protection 
Act. In this country, Puumala virus 
(PUUV) causes most clinical hantavi-
rus cases, although Dobrava-Belgrade 
virus and Tula virus also circulate (1). 
From 2001 through 2006, an aver-
age of ≈220 cases were reported per 
year (incidence 0.267/100,000) with 
a maximum of 448 cases in 2005. In 
contrast, 1,687 cases were reported in 
2007 (2). Whereas in 2005 the highest 
incidence of infection was in metro-
politan areas (3), the current outbreak 
is focused in the rural areas in southern 
and western Germany. Clinical case-
patients exhibit key characteristics of 
hantavirus disease (nephropathia epi-
demica): acute high fever; pain in the 
back, head, and/or abdomen; protei-
nuria; rise of serum creatinine; throm-
bocytopenia; and renal failure (1). 
The outbreak provided considerable 
numbers of clinical samples from the 
viremic phase and thus has enabled a 
molecular epidemiologic analysis of 
the circulating virus.
At the National Consultation Lab-
oratory for Hantavirus Infections (Ber-
lin), we received early-phase serum 
specimens from the outbreak regions 
for conﬁ   rmation assays. In enzyme 
immunoassays and Western blot tests 
(4), 80 samples from patients during 
the early clinical phase were positive 
for PUUV-speciﬁ  c  immunoglobulin 
(Ig) M antibodies. All IgM data were 
accompanied by simultaneous or sub-
sequent detection of PUUV-speciﬁ  c 
IgG. The samples were screened for 
hantavirus RNA by reverse transcrip-
tion–PCR (RT-PCR) (5). Of the 80 
early-phase serum samples, 42 (53%) 
were RT-PCR positive. For a subset 
of 14 of the 42 samples, a 557-nt seg-
ment of the nucleocapsid (S) gene un-
derwent nucleotide sequence analysis 
as described previously (6).
The Figure, panel A, shows a 
map of Germany with the residences 
of those patients from whom virus 
sequences were ampliﬁ  ed  (marked 
by letter H in front of the specimen 
number). In the phylogenetic analy-
sis, despite a substantial evolutionary 
distance to PUUV strains from other 
parts of Europe, the virus sequences 
unambiguously grouped within the 
PUUV species (Figure, panel B). The 
few previously known human PUUV 
sequences from individual clinical 
case-patients in Germany, “Berkel” 
from Munsterland (7) and “Heidel-
berg” from a region located between 
Swabian Jura and Spessart Forest 
(8), as well as human-derived strains 
from a small 2004 outbreak in the 
Bavarian Forest (6), were included 
in this analysis. The results showed a 
clustering of the new viral sequences 
strictly according to residential areas 
of the patients, forming the following 
4 clades: Swabian Jura (SJ), Spessart 
Forest (SF), Munsterland (ML), and 
Bavarian Forest (BF). Two different 
single sequences, Karlsruhe (from a 
region in northwestern Swabian Jura) 
and Essen (in southern Munster-
land), represent 2 putative additional 
lineages.